drughunter.com
< 1 minute read
Sep. 30, 2024

August 2024 Annotated Searchable Patent Table

Editor:  
Loading...

twitterlinkedinemail

Other articles you may be interested in

March 2024 Patent Highlights: OX2R Agonists, TEAD Covalent Inhibitors, NaV1.8 Inhibitors, LRRK2 Inhibitors, and More

In March 2024, the landscape of patent disclosures continued to reflect the rapid pace of advances against key therapeutic targets. The Drug Hunter team has curated a searchable database encompassing over 200 patents pertinent to the field of drug discovery. This resource is further enriched with insightful spotlight on some of the most promising molecules and targets, including OX2R agonists, TEAD covalent inhibitors, NaV1.8 inhibitors, and selective PI3Kγ inhibitors, among others. This round-up provides a valuable tool for drug hunters to navigate the most recent trends in drug discovery.

Highly Selective TREX1 Inhibitors from Constellation Pharmaceuticals

This article highlights a patent application from Constellation Pharmaceuticals that discloses the biological activity of compounds that act as TREX1 inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

Patent Highlights from January 2024: KRAS G12V, MAGL, and WRN Inhibitors, Nrf2 Degraders, and More

From WRN helicase to KRAS G12V, there were numerous hot targets of interest with patent applications published in January 2024. Here, we curated a searchable table comprising key information for more than 200 patents from January 2024 of potential interest to drug hunters, along with highlights from some of our favorites, including several degraders and molecules targeting Nrf2, KRAS G12V, MAGL, WRN, among others.

May 2024 Patent Highlights: STING Antagonists, WIZ Degraders, Macrocyclic Amine-Based OX2R Modulators, and More

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in May 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as STING antagonists, WIZ degraders, RNA degraders, and macrocyclic amine-based OX2R modulators.

How Might Puhe BioPharma’s WRN Helicase Inhibitors Differentiate from Novartis’?

This article highlights a patent application from Puhe BioPharma that discloses the biological activity of compounds that act as WRN helicase inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.